Cargando…

Toll-Like Receptor 4 Expression on Lymphoma Cells Is Critical for Therapeutic Activity of Intratumoral Therapy With Synthetic TLR4 Agonist Glucopyranosyl Lipid A

Intratumoral (IT) injections of Glucopyranosyl lipid A (G100), a synthetic toll-like receptor 4 (TLR4) agonist formulated in a stable emulsion, resulted in T-cell inflammation of the tumor microenvironment (TME) and complete cure of 60% of mice with large established A20 lymphomas. Strong abscopal e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Hailing, Betancur, Alec, Chen, Michael, ter Meulen, Jan H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466407/ https://www.ncbi.nlm.nih.gov/pubmed/32974162 http://dx.doi.org/10.3389/fonc.2020.01438

Ejemplares similares

Molecular and Cellular Response Profiles Induced by the TLR4 Agonist-Based Adjuvant Glucopyranosyl Lipid A
por: Lambert, Stacie L., et al.
Publicado: (2012)

Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 Agonist, Promotes Potent Systemic and Mucosal Responses to Intranasal Immunization with HIVgp140
por: Arias, Mauricio A., et al.
Publicado: (2012)

Intratumoral injections of G100 (synthetic TLR4 agonist) increase trafficking of lentiviral vector-induced antigen-specific CD8 T cells to the tumor microenvironment
por: Albershardt, Tina C, et al.
Publicado: (2015)

Intratumoral immune activation with TLR4 agonist synergizes with effector T cells to eradicate established murine tumors
por: Albershardt, Tina C., et al.
Publicado: (2020)

A "prime-pull" immunotherapy approach using a lentiviral vector and intratumoral TLR4 agonist redirects cytotoxic T cells
por: Albershardt, Tina C, et al.
Publicado: (2014)

Synthetic Toll Like Receptor-4 (TLR-4) Agonist Peptides as a Novel Class of Adjuvants
por: Shanmugam, Arulkumaran, et al.
Publicado: (2012)

Development and Characterization of Synthetic Glucopyranosyl Lipid Adjuvant System as a Vaccine Adjuvant
por: Coler, Rhea N., et al.
Publicado: (2011)

Intratumoral expression of IL-12 from lentiviral or RNA vectors acts synergistically with TLR4 agonist (GLA) to generate anti-tumor immunological memory
por: Leleux, Jardin A., et al.
Publicado: (2021)

Schistosoma mansoni antigen Sm-p80: prophylactic efficacy using TLR4 agonist vaccine adjuvant glucopyranosyl lipid A-Alum in murine and non-human primate models
por: Zhang, Weidong, et al.
Publicado: (2018)

Physicochemical characterization of biological and synthetic forms of two lipid A-based TLR4 agonists
por: Hu, Gang, et al.
Publicado: (2023)

Prevention and Mitigation of Acute Radiation Syndrome in Mice by Synthetic Lipopeptide Agonists of Toll-Like Receptor 2 (TLR2)
por: Shakhov, Alexander N., et al.
Publicado: (2012)

Intratumoral immunotherapy with the TLR7/8 agonist 3M-052
por: Smirnov, DV, et al.
Publicado: (2013)

Innate and Adaptive Responses of Intratumoral Immunotherapy with Endosomal Toll-Like Receptor Agonists
por: Andón, Fernando Torres, et al.
Publicado: (2022)

Synthetic glycan-based TLR4 agonists targeting caspase-4/11 for the development of adjuvants and immunotherapeutics
por: Adanitsch, Florian, et al.
Publicado: (2018)

Solid Lipid Nanoparticle Carrier Platform Containing Synthetic TLR4 Agonist Mediates Non-Viral DNA Vaccine Delivery
por: Francis, Jasmine E., et al.
Publicado: (2020)

Should a Toll-like receptor 4 (TLR-4) agonist or antagonist be designed to treat cancer? TLR-4: its expression and effects in the ten most common cancers
por: Mai, Chun Wai, et al.
Publicado: (2013)

Toll-Like Receptor 4 (TLR4) and Typhoid Fever in Vietnam
por: Hue, Nguyen Thi, et al.
Publicado: (2009)

Trial Watch: Toll-like receptor agonists in oncological indications
por: Aranda, Fernando, et al.
Publicado: (2014)

TLR4 Agonist Monophosphoryl Lipid A Alleviated Radiation-Induced Intestinal Injury
por: Guo, Jiaming, et al.
Publicado: (2019)

Coordinated Activation of Toll-Like Receptor8 (TLR8) and NLRP3 by the TLR8 Agonist, VTX-2337, Ignites Tumoricidal Natural Killer Cell Activity
por: Dietsch, Gregory N., et al.
Publicado: (2016)

Combination with Toll-like receptor 4 (TLR4) agonist reverses GITR agonism mediated M2 polarization of macrophage in Hepatocellular carcinoma
por: Pan, Caixu, et al.
Publicado: (2022)

A critical role of toll-like receptor 4 (TLR4) and its' in vivo ligands in basal radio-resistance
por: Liu, C, et al.
Publicado: (2013)

Phylogenetic variation and polymorphism at the Toll-like receptor 4 locus (TLR4)
por: Smirnova, Irina, et al.
Publicado: (2000)

Toll-Like Receptor 4 (TLR4) and AMPK Relevance in Cardiovascular Disease
por: Vaez, Haleh, et al.
Publicado: (2023)

Toll-like receptor 4 (TLR4): new insight immune and aging
por: Kim, Hyo-Jin, et al.
Publicado: (2023)

NOD2 Agonist Promotes the Production of Inflammatory Cytokines in VSMC in Synergy with TLR2 and TLR4 Agonists
por: Sun, Jinghua, et al.
Publicado: (2012)

Formulated Phospholipids as Non-Canonical TLR4 Agonists
por: Liang, Hong, et al.
Publicado: (2022)

Toll-Like Receptor (TLR2 and TLR4) Polymorphisms and Chronic Obstructive Pulmonary Disease
por: Budulac, Simona E., et al.
Publicado: (2012)

Expression of Toll-Like Receptors (TLR2 and TLR4) in the Eyes of Mice with Disseminated Acanthamoebiasis
por: Kot, Karolina, et al.
Publicado: (2019)

TLR2 and TLR4 in Parkinson’s disease pathogenesis: the environment takes a toll on the gut
por: Gorecki, Anastazja M., et al.
Publicado: (2021)

Endotoxin-tolerant Mice Have Mutations in Toll-like Receptor 4 (Tlr4)
por: Qureshi, Salman T., et al.
Publicado: (1999)

The Role of Carbohydrates in the Lipopolysaccharide (LPS)/Toll-Like Receptor 4 (TLR4) Signalling
por: Cochet, Florent, et al.
Publicado: (2017)

Toll-like receptor 4 (TLR4) antagonists as potential therapeutics for intestinal inflammation
por: Tam, Janine S. Y., et al.
Publicado: (2021)

Phytochemicals targeting Toll-like receptors 4 (TLR4) in inflammatory bowel disease
por: Dai, Wenbin, et al.
Publicado: (2022)

Recent advances in the role of toll-like receptors and TLR agonists in immunotherapy for human glioma
por: Deng, Shuanglin, et al.
Publicado: (2014)

A protein associated with Toll-like receptor (TLR) 4 (PRAT4A) is required for TLR-dependent immune responses
por: Takahashi, Koichiro, et al.
Publicado: (2007)

Design and Synthesis of 3-(β-d-Glucopyranosyl)-4-amino/4-guanidino Pyrazole Derivatives and Analysis of Their Glycogen Phosphorylase Inhibitory Potential
por: Kun, Sándor, et al.
Publicado: (2023)

Toll-Like Receptor (TLR) 2 and TLR4 Differentially Regulate Doxorubicin Induced Cardiomyopathy in Mice
por: Ma, Yonggang, et al.
Publicado: (2012)

Clinical Implication of Toll-Like Receptors (TLR2 and TLR4) in Acute Myeloid Leukemia Patients
por: Aref, Salah, et al.
Publicado: (2020)

TLR Agonists for Cancer Immunotherapy: Tipping the Balance between the Immune Stimulatory and Inhibitory Effects
por: Lu, Hailing
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_5781femf2mqgc7ir2llnfecgfr